On May 23, 2022 Chia Tai‑Tianqing Pharma (CTTQ), a Nanjing subsidiary of Sino Biopharma, reported that it will acquire global rights to an anti-LAG3 mAb from Symphogen A/S of Denmark (Press release, ChinaBio, MAY 23, 2022, View Source [SID1234615011]). Sym022 is a mAb that binds LAG3 to block the interaction with MHCII, which increases T cell proliferation and production of cytokines . In two Phase I trials, Sym022 proved itself to be safe and well-tolerated as a monotherapy and in combination with checkpoint inhibitors. Financial details of the transaction were not disclosed. Symphogen is the Antibody Center of Excellence for Servier, a privately held French biopharma.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!